Biktarvy is a single-tablet, once-daily HIV regimen combining bictegravir with emtricitabine and tenofovir alafenamide. It is the most prescribed HIV treatment globally, preferred for high efficacy, high barrier to resistance, and favorable safety.
Bictegravir inhibits HIV integrase, preventing viral DNA integration. Emtricitabine and tenofovir alafenamide are NRTIs blocking viral RNA-to-DNA conversion. Three-drug combo provides synergistic HIV suppression.
Annual revenue trajectory
Revenue of competing drugs in the same class
1 indications
All approved therapeutic uses
Biktarvy is the #1 prescribed HIV regimen globally with ~40% market share. Dominance driven by high barrier to resistance, single-tablet convenience, and no HLA-B*5701 testing needed.
Projected to reach $13B+ by 2026. Long-acting injectable competition from ViiV’s Cabenuva is primary threat. Gilead developing lenacapavir (twice-yearly injection) to extend HIV franchise.
| Drug | Company | Revenue |
|---|---|---|
| Triumeq (dolutegravir/ABC/3TC) | ViiV (GSK) | $2.5B |
| Dovato (dolutegravir/3TC) | ViiV (GSK) | $2.0B |
| Cabenuva (cabotegravir/rilpivirine) | ViiV (GSK) | $1.5B |
| Symtuza (darunavir/c/FTC/TAF) | J&J | $0.5B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.